CytomX Therapeutics (CTMX) Revenue & Revenue Breakdown
CytomX Therapeutics Revenue Highlights
Latest Revenue (Y)
$138.10M
Latest Revenue (Q)
$50.92M
CytomX Therapeutics Revenue by Period
CytomX Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $138.10M | 36.45% |
| 2023-12-31 | $101.21M | 90.38% |
| 2022-12-31 | $53.16M | -23.59% |
| 2021-12-31 | $69.57M | -30.68% |
| 2020-12-31 | $100.36M | 74.58% |
| 2019-12-31 | $57.49M | -3.38% |
| 2018-12-31 | $59.50M | -16.92% |
| 2017-12-31 | $71.62M | 376.12% |
| 2016-12-31 | $15.04M | 95.06% |
| 2015-12-31 | $7.71M | 51.90% |
| 2014-12-31 | $5.08M | 471.73% |
| 2013-12-31 | $888.00K | - |
CytomX Therapeutics generated $138.10M in revenue during NA 2024, up 36.45% compared to the previous quarter, and up 240.23% compared to the same period a year ago.
CytomX Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $50.92M | 33.66% |
| 2024-12-31 | $38.09M | 13.94% |
| 2024-09-30 | $33.43M | 33.12% |
| 2024-06-30 | $25.11M | -39.43% |
| 2024-03-31 | $41.46M | 55.83% |
| 2023-12-31 | $26.61M | 0.85% |
| 2023-09-30 | $26.38M | 6.71% |
| 2023-06-30 | $24.72M | 5.21% |
| 2023-03-31 | $23.50M | 2384.04% |
| 2022-12-31 | $946.00K | -94.41% |
| 2022-09-30 | $16.91M | -6.88% |
| 2022-06-30 | $18.16M | 6.00% |
| 2022-03-31 | $17.14M | -13.13% |
| 2021-12-31 | $19.73M | 12.17% |
| 2021-09-30 | $17.59M | 7.98% |
| 2021-06-30 | $16.29M | 1.98% |
| 2021-03-31 | $15.97M | -2.46% |
| 2020-12-31 | $16.37M | -7.95% |
| 2020-09-30 | $17.79M | 7.11% |
| 2020-06-30 | $16.61M | -66.51% |
| 2020-03-31 | $49.59M | 499.02% |
| 2019-12-31 | $8.28M | -22.71% |
| 2019-09-30 | $10.71M | 18.85% |
| 2019-06-30 | $9.01M | -69.43% |
| 2019-03-31 | $29.48M | 157.04% |
| 2018-12-31 | $11.47M | -8.30% |
| 2018-09-30 | $12.51M | -41.38% |
| 2018-06-30 | $21.34M | 50.44% |
| 2018-03-31 | $14.18M | -47.61% |
| 2017-12-31 | $27.07M | 12.13% |
| 2017-09-30 | $24.14M | 175.87% |
| 2017-06-30 | $8.75M | -24.89% |
| 2017-03-31 | $11.65M | 85.79% |
| 2016-12-31 | $6.27M | 81.59% |
| 2016-09-30 | $3.45M | 11.64% |
| 2016-06-30 | $3.09M | 39.18% |
| 2016-03-31 | $2.22M | 11.82% |
| 2015-12-31 | $1.99M | 2.53% |
| 2015-09-30 | $1.94M | -5.09% |
| 2015-06-30 | $2.04M | 17.28% |
| 2015-03-31 | $1.74M | -6.39% |
| 2014-12-31 | $1.86M | -2.82% |
| 2014-09-30 | $1.92M | - |
CytomX Therapeutics generated $50.92M in revenue during Q1 2025, up 33.66% compared to the previous quarter, and up 191.37% compared to the same period a year ago.
CytomX Therapeutics Revenue Breakdown
CytomX Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Mar 25 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|
| E G F R Products | $8.40M | $42.30M | $43.70M | - |
| License And Service | - | $2.80M | - | - |
| Amgen Other Products | - | - | $4.20M | $4.40M |
Latest
CytomX Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: E G F R Products (100.00%).
CytomX Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|
| License And Service | $2.80M | - | - |
| Amgen Other Products | - | $4.20M | $4.40M |
| E G F R Products | - | $42.30M | $43.70M |
Latest
CytomX Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 18: License And Service (100.00%).
CytomX Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RIGL | Rigel Pharmaceuticals | $179.28M | $101.69M |
| ARCT | Arcturus Therapeutics | $152.31M | $28.30M |
| CTMX | CytomX Therapeutics | $138.10M | $50.92M |
| PRTA | Prothena | $135.16M | $4.42M |
| GOSS | Gossamer Bio | $114.70M | $11.49M |
| RGNX | REGENXBIO | $83.33M | $21.36M |
| BCYC | Bicycle Therapeutics | $35.27M | $9.98M |
| LXRX | Lexicon Pharmaceuticals | $31.08M | $28.87M |
| VSTM | Verastem | $10.00M | - |
| ABSI | Absci | $4.53M | $593.00K |
| KALV | KalVista Pharmaceuticals | - | $1.43M |